RecruitingPhase 4NCT05412394
Once Weekly Infant Corticosteroid Trial for DMD
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
Sponsor
Anne M. Connolly
Enrollment
26 participants
Start Date
Apr 30, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Eligibility
Sex: MALEMin Age: 1 MonthMax Age: 30 Months
Inclusion Criteria2
- Subjects ages 1 month through 30 months
- Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.
Exclusion Criteria1
- Prior treatment with Glucocorticosteroids
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPrednisolone
Liquid, 5mg/kg per week, for one year
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05412394
Related Trials
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT0728718919 locations
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT0645063925 locations
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT068173829 locations
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT062802098 locations
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT0599600325 locations